Gong Wangang, Wang Lifang, Zheng Zhiguo, Chen Wenhu, Du Peng, Zhao Hongguang
Institute of Cancer and Basic Medicine (ICBM), Chinese Academy of Sciences, Hangzhou 310022, China.
Zhejiang Cancer Research Institute, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou 310022, China.
Transl Cancer Res. 2020 Jan;9(1):95-103. doi: 10.21037/tcr.2019.11.21.
Cyclin-dependent kinase 6 (CDK6) is an important regulatory protein of the cell cycle and plays an important role in tumor progression. The aim of this study was to investigate the expression of CDK6 in T1 stage non-small cell lung cancer (NSCLC) and to explore the association of CDK6 with the clinicopathological features of the disease.
CDK6 expression was analyzed by real-time PCR (RT-PCR) and immunohistochemistry (IHC) in tumor tissue samples and the distal normal tissue samples from 56 T1 stage NSCLC patients. The correlation between CDK6 expression and clinicopathological features was analyzed using the independent samples -test and nonparametric tests.
We found CDK6 had a tendency to increase in tumor tissues compared to normal tissues at the transcriptional level (P=0.073). Moreover, the expression of CDK6 protein in NSCLC tissues was also significantly higher than in normal lung tissues (P=0.003). With an increase of smoking quantity, the expression of mRNA was increased (P=0.009). Remarkably, CDK6 expression was increased in squamous cell carcinoma (SCC) tissues but decreased in adenocarcinoma (AD) tissues at both the transcription and protein levels (P<0.001). After stratification based on pathological type, gene expression was not associated with any clinicopathological features in SCC, while it was negatively associated with tumor diameter in AD (P=0.049).
Taken together, these results indicated that abnormal expression of the gene in NSCLC might be associated with pathological type, which may serve as a diagnostic biomarker for NSCLC.
细胞周期蛋白依赖性激酶6（CDK6）是细胞周期的重要调节蛋白，在肿瘤进展中起重要作用。本研究旨在探讨CDK6在T1期非小细胞肺癌（NSCLC）中的表达，并探讨CDK6与该疾病临床病理特征的相关性。
采用实时荧光定量PCR（RT-PCR）和免疫组织化学（IHC）方法分析56例T1期NSCLC患者肿瘤组织样本和远端正常组织样本中CDK6的表达。采用独立样本t检验和非参数检验分析CDK6表达与临床病理特征的相关性。
我们发现，在转录水平上，与正常组织相比，肿瘤组织中CDK6有升高的趋势（P=0.073）。此外，NSCLC组织中CDK6蛋白的表达也明显高于正常肺组织（P=0.003）。随着吸烟量的增加，mRNA的表达增加（P=0.009）。值得注意的是，在转录和蛋白水平上，CDK6在鳞状细胞癌（SCC）组织中的表达增加，而在腺癌（AD）组织中的表达降低（P<0.001）。根据病理类型分层后，SCC中基因表达与任何临床病理特征均无相关性，而在AD中与肿瘤直径呈负相关（P=0.049）。
综上所述，这些结果表明NSCLC中该基因的异常表达可能与病理类型有关，这可能作为NSCLC的诊断生物标志物。
